Evolocumab intensive lipid-lowering therapy on prognosis of post-cerebral infarction depression

Table 2 Longitudinal depression severity and treatment response, n (%)/mean ± SD

Time point/outcome	Intensive group (n = 72)	Standard group (n = 72)	P value
HAMD-17 total score
Baseline	20.6 ± 4.8	20.1 ± 4.5	0.510
Week 4	17.8 ± 4.2	19.1 ± 4.3	0.074
Week 8	15.2 ± 3.6	17.4 ± 3.9	0.001
Week 12	11.4 ± 3.3	15.2 ± 4.1	< 0.001
Week 24	7.8 ± 2.9	12.5 ± 3.6	< 0.001
Treatment response (≥ 50 reduction from baseline)
Week 12	45 (62.5)	27 (37.5)	0.002
Week 24	57 (79.2)	36 (50.0)	< 0.001
Remission (HAMD-17 < 7)
Week 12	21 (29.2)	9 (12.5)	0.013
Week 24	42 (58.3)	23 (31.9)	0.001
Time to response (weeks)	8.3 ± 2.1	11.7 ± 3.4	< 0.001
Time to remission (weeks)	16.5 ± 4.2	20.8 ± 3.9	< 0.001

Treatment response defined as ≥ 50% reduction in 17-item Hamilton Depression Rating Scale score from baseline. Remission defined as 17-item Hamilton Depression Rating Scale score < 7. HAMD-17: 17-item Hamilton Depression Rating Scale.